Varian
VC Fund
Palo Alto, United States
Varian is a VC fund in Palo Alto focused on Health Care and Medical. Varian Medical Systems, headquartered globally in Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics,radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries Varian invests in
Stages Varian invests in
Countries Varian invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Investment Focus
Industry
- Health Care 7 (41%)
- Medical 6 (35%)
- Medical Device 6 (35%)
- Biotechnology 3 (18%)
- Manufacturing 2 (12%)
Stage
- Series B 5 (29%)
- Series C 3 (18%)
- Funding Round 2 (12%)
- Series A 1 (6%)
- Debt Financing 1 (6%)
Country
- United States 7 (41%)
- Canada 2 (12%)
- Israel 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ben Moga
Director, Strategic Alliances
|
Director, Strategic Alliances | Total investments: 0 | Find email | |
Darin Bartik
Director, Marketing & Strategy, Medical Oncology Software
|
Director, Marketing & Strategy, Medical Oncology Software | Total investments: 0 | Find email | |
Dow Wilson
President and Chief Executive Officer
|
President and Chief Executive Officer | Total investments: 0 | Find email | |
Kolleen Kennedy
President, Proton Solutions and Chief Growth Officer
|
President, Proton Solutions and Chief Growth Officer | Total investments: 0 | Find email | |
Rafael Torres
Senior Vice President, Business Development and Strategy
|
Senior Vice President, Business Development and Strategy | Total investments: 4 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Lucata leverages patented migrating thread technology to massively scale unified memory and conduct high performance, multi-hop analytics, including exhaustive breadth-first search (BFS), on unpruned and unsharded databases with 1 trillion vertices and beyond. Organizations can now use their existing graph database software or custom graphsolutions to analyze deeper connections on much larger graphs than ever before possible. Lucata solutions support groundbreaking graph analytics and improved machine learning and AI for organizations in financial services, cybersecurity, blockchain, healthcare, pharmaceuticals, telecommunications, ecommerce, government and more. The company has offices in Palo Alto, New York City, and South Bend, Ind. For more information, visit www.Lucata.com. Key technical claims: 1. Data doesn’t move, processing context moves to the data in a global unified address space. 2. Latency of both network and memory access are hidden due to the migrating threads and multithreaded Lucata cores. 3. Energy efficient high density memory architecture. 4. Drastic reduction in OS intervention. 5. Architecture doesn't rely on data locality for optimal performance. 6. Linear performance growth with hardware scale up to 64,000 nodes. 7. Single shared address space up to 18 Exabytes. | $11.9M / Series B / Apr 22, 2021 | ||
| Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in themedical field. | Series B / Mar 25, 2021 | ||
| COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research. | $10M / Debt Financing / Nov 10, 2020 | ||
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $40M / Series C / Jun 08, 2020 | ||
| Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. | $28M / Series C / May 29, 2020 | ||
| ZAP Surgical Systems is a medical company that designs and manufactures a radiosurgery platform for treating brain tumors. | $81M / Private Equity / Jan 08, 2020 | ||
| Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology. Founded in 2014, Oncora's intuitive software platform allows for better collection and application of real world data for all healthcare related decisions, for the benefit of the patient. | $3M / Corporate Round / Sep 15, 2019 | ||
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $54.7M / Series C / Apr 08, 2019 | ||
| ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors. The company is dedicated to transforming an interventional radiology procedure called embolization. | $30M / Series B / Apr 08, 2019 | ||
| Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre.Fusion’s deepradiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link the most effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell.Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize into targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity. | $105M / Series B / Apr 01, 2019 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Varian invest in?
Varian invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Varian?
Public channels for Varian include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Varian?
The team at Varian includes Ben Moga (Director, Strategic Alliances), Darin Bartik (Director, Marketing & Strategy, Medical Oncology Software) and Dow Wilson (President and Chief Executive Officer), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
